HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $4.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained a price target of $4.5.
December 19, 2023 | 11:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Unicycive Therapeutics and maintained a $4.5 price target.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst like Ed Arce can instill confidence in investors and potentially lead to a positive short term impact on UNCY's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100